ANIK
ANIK
Positions held
Your positionsANIK isn't in your positions.
Add it to see shares, cost, and P&L here.
Fundamentals
| Market cap | — | Enterprise value | — | Trailing P/E | — | Forward P/E | — |
| PEG | — | Price / book | — | Beta | — | Dividend yield | — |
| Revenue growth | — | Earnings growth | — | Gross margin | — | Operating margin | — |
| Profit margin | — | ROE | — | ROA | — | Debt / equity | — |
| Current ratio | — | Free cash flow | — | Analyst recommendation | — | Mean target | — |
| 52w high | — | 52w low | — |
Quarterly
No data yet.
Yearly (6y)
No data yet.
No flags
• No distress or material-risk keywords in recent headlines (keyword scan only — not a guarantee).
News
2026-09-25 · Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study
2026-09-25 · Is Anika Therapeutics (ANIK) Outperforming Other Medical Stocks This Year?
2026-09-23 · AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study
2026-09-21 · NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication
2026-09-18 · PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
2026-09-16 · RCKT Aligns With FDA on Completing Phase II Study in Danon Disease
2026-09-15 · Immunocore Hits Enrollment Target in Kimmtrak Label Expansion Study
2026-09-10 · Roche Gets FDA Priority Tag for Enspryng in Rare Autoimmune Disorder
2026-09-09 · Novartis' Del-desiran Fails Late-Stage DM1 Study, Shares Fall
2026-09-09 · FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
2026-09-04 · ABBV's Etentamig Meets Goals in Phase III Multiple Myeloma Study
2026-09-03 · TEVA's TEV '408 Meets Goal in Phase IIa Celiac Disease Study
Price (daily)
Full chart · RSI · MACD · patterns